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Abstract: In the present study we have performed both a meta-analysis and an analytical 
study exploring the presence of Chlamydia pneumoniae, herpes simplex virus type 1, human 
herpes virus 6, and Toxoplasma gondii antibodies in a sample of 143 schizophrenic patients 
and 143 control subjects. The meta-analysis was performed on papers published up to 
April 2014. The presence of serum immunoglobulin G and immunoglobulin A was performed 
by enzyme-linked immunosorbent assay test. The detection of microbial DNA in total periph-
eral blood was performed by nested polymerase chain reaction. The meta-analysis showed 
that: 1) C. pneumoniae DNA in blood and brain are more common in schizophrenic patients; 
2) there is association with parasitism by T. gondii, despite the existence of publication bias; 
and 3) herpes viruses were not more common in schizophrenic patients. In our sample only 
anti-Toxoplasma immunoglobulin G was more prevalent and may be a risk factor related to 
schizophrenia, with potential value for prevention.
Keywords: meta-analysis, analytical study, Chlamydia pneumoniae, herpes simplex virus type 1, 
human herpes virus 6, Toxoplasma gondii, schizophrenia
Introduction
The word “schizophrenia” refers to a group of disabling mental disorders characterized 
by alterations in perception, thought, affectivity, and behavior. Its etiology is unknown 
and there are no curative treatments.1 Although present worldwide, schizophrenia is 
more prevalent in developed countries, where the accumulated lifetime prevalence 
can reach more than 1% and an annual incidence of five cases per 10,000 people.2 
A possible genetic vulnerability exists for schizophrenia, as supported by the increased 
familial morbid risk for schizophrenia found in first-degree relatives of affected sub-
jects, possibly in conjunction with the influence of environmental factors. Prenatal 
and perinatal obstetric complications have also been related to schizophrenia, and 
some authors postulate that environmental factors (such as trauma, cannabis use, or 
neurotropic infections) might modulate the final impact of such complications on the 
early genetic alterations described for this illness.3
Among other environmental risk factors for schizophrenia, infectious factors 
have been posed, a hypothesis that would be supported by some studies describing an 
increased prevalence for the illness among those subjects born during winter and spring 
months in the northern hemisphere.4 Indeed, prevalence has been reported as being 
much higher following flu epidemics. Several infectious agents could harm a fetus. 
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Being primarily neurotropic agents or not, acting directly or 
in an immune-mediated way, or perpetuating themselves or 
not, these agents could facilitate the occurrence of irrevers-
ible neurologic injuries associated with alterations in both 
neurotransmission expression and sensorial information 
processing,5 which may have a role in the development of 
schizophrenia later in life. These subjects may potentially 
benefit from antimicrobial treatment, which may improve 
their outcome.
Among all the infectious agents that have been studied 
in schizophrenia, Chlamydia pneumoniae, herpes simplex 
virus type 1 (HSV-1), human herpes virus 6 (HHV-6) and 
Toxoplasma gondii are especially interesting because they are 
neurotropic, they cause illnesses that could share symptoms 
with schizophrenia, and they can block neural function in 
a recurrent manner as they produce latent infections with 
potential reactivations. Although such possibilities are 
biologically plausible, the association between microbial 
agents and schizophrenia is not conclusive.6 The present 
study aimed to explore such associations via both a meta-
analysis and an analytical study exploring the presence of 
the abovementioned infectious agents in a sample of patients 
with schizophrenia and controls.
Materials and methods
Meta-analysis
The meta-analysis was performed according to the same 
procedure used in a paper published by our group 3 years 
ago.6 Thus, in brief, we performed a systematic search of all 
articles published in English or Spanish in journals indexed 
on MEDLINE, psycINFO, ISI Web of Knowledge, and the 
Cochrane Library up to April 2014. The search terms used 
were “schizophrenia” and “herpes” or “Chlamydia pneu-
moniae” or “Chlamydophila pneumoniae” or “Toxoplasma 
gondii.” After that search, we excluded a group of papers 
including noncontrolled cohort studies, reviews, studies 
that did not present their results in a correct and/or explicit 
manner, animal studies, studies where the control group 
comprised patients with other psychiatric or neurological 
disorders, and those that did not assess the infectious pro-
cesses. On the other hand, included studies were those that 
examined patients and healthy controls (characterized by 
absence of psychiatric disorders or any neurological disease), 
cohort studies of patients and controls, and case series. 
It was required that schizophrenic patients were included 
in the studies, and that the aim of the study was the direct 
or indirect exploration of the possible association between 
infection and schizophrenia.
The following data were obtained for each serologic or 
molecular determination in each publication: odds ratios 
(OR) and their 95% confidence intervals (CI), population 
weights, and statistical significance of the analyses. The 
DerSimonian and Laird method was used as it produces over-
all estimates that are less affected by heterogeneity among 
studies.7 Heterogeneity among studies was determined using 
Cochran’s Q statistic method when the number of papers 
included was five or more. Additionally, Higgins I2 was also 
used as a measure of total OR variability given heterogeneity 
among studies. Hence, very high values of the latter measure, 
above 75%, would indicate a strong heterogeneity, suggesting 
the need to carry out an additional meta-regression using the 
restricted maximum likelihood method. In such cases, we 
also performed a more detailed subanalysis of the different 
subgroups, when the number of studies to be included in each 
subgroup was big enough (three or more). As a whole, we 
considered that no relationship existed between exposure to 
microorganisms and the presence of schizophrenia when the 
95% CI included the one unit value.8
Begg’s and Egger’s tests were used when the number 
of studies included was five or more, in order to check for 
any particular publication biases and their magnitude.9,10 
Study quality was assessed using the Newcastle-Ottawa 
Quality Assessment Scale (Available from: http://www.ohri.
ca/programs/clinical_epidemiology/oxford.htm; updated 
15 June 2014). Data obtained from the various studies were 
analysed using the STATA Release 10.1 statistical package 
(StataCorp LP, College Station, TX, USA).
analytical study of infectious agents
sample characteristics: patients with schizophrenia
Patients with a diagnosis of schizophrenia and less than 5 years 
since their first episode (n=143) were invited to participate 
in the study. Patients were recruited from the Mental Health 
Services of Jerez de la Frontera and Jaen (south Spain). 
All patients fulfilled ICD10 (International Statistical Classifica-
tion of Diseases and Related Health Problems, 10th Revision) 
criteria for schizophrenia. They were assessed using a Spanish 
validated version of the Schedules for Clinical Assessments 
in Neuropsychiatry. Stability in diagnosis during the last year 
and no changes in treatment for the last 2 months were also 
taken into account as inclusion criteria. All patients signed an 
informed consent prior to being included in the study.
sample characteristics: control subjects
The control group comprised 143 unrelated individuals with 
no personal or family history of mental disorders or suicide 
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and with no pharmacological or psychological treatment 
that could interfere with the neuropsychological assessment. 
A specifically trained psychologist interviewed each par-
ticipant and used the Schedules for Clinical Assessments in 
Neuropsychiatry to check the absence of these conditions. 
They all came from different primary care centers belonging 
to the Primary Care catchment area of south Granada (Spain). 
All participants were nonimmunosuppressed and signed an 
informed consent prior to being included in the study.
Controls were stratified by age and sex with cases. In both 
groups, sex was equally distributed (62.24% of cases and 
62.94% of controls were male subjects; chi-square =0.001, 
P=0.973) and mean age was also comparable between cases 
and controls (28.69 [standard deviation =5.41] versus 30.42 
[standard deviation =5.62] respectively; t=1.771, P=0.079).
After losing some laboratory samples for different rea-
sons, our final count was 271 blood samples (128 cases and 
143 controls) and 284 plasma samples (142 cases and 142 
controls). A microbiological study with these samples was 
made using the following procedures.
Specific serum immunoglobulins
Different commercial kits were used to detect different micro-
bial immunoglobulin Gs (IgGs): the HERPES SIMPLEX 1 
ELISA (enzyme-linked immunosorbent assay) IgG kit 
system developed by Vircell (Granada, Spain); the TOXO-
PLASMA ELISA IgG kit, also distributed by Vircell; the 
human HERPESVIRUS 6 ELISA IgG kit designed by Alere 
Healthcare (Barcelona, Spain); and the CHLAMYDOPHILA 
PNEUMONIAE ELISA IgG kit, developed by Savyon Diag-
nostics (Madrid, Spain). C. pneumoniae immunoglobulin A 
(IgA) was analyzed using a specific kit designed by Vircell 
(Granada, Spain). As for the rest of the IgA measurements, 
the assay was previously standardized by using the same solid 
phase previously used for IgG, a human anti-IgA conjugate 
(Siemens Lab, Barcelona, Spain), and a commercialized, 
specific IgA positive control with known concentration 
(Lab. Aviva Systems Biology, San Diego, CA, USA). Serum 
was diluted using anti-IgG. To determine the working dilu-
tion for both the conjugate and the positive control, dilutions 
of both were prepared. These were then doubly processed, 
comparing the average absorption result against the negative 
control. The sample was considered positive in detecting IgA 
when well absorbance was equal to or greater than double the 
threshold positive value. Samples were processed in dupli-
cate according to our routine laboratory method. The mean 
absorbance value was used in the evaluation. The coefficients 
of variation of the ELISA were less than 10%.
Detection of peripheral-blood microbial DNa
DNA was extracted using ReliaPrep™ Blood gDNA Mini-
prep System (Promega Biotech Iberica, Madrid, Spain). 
Specific DNA was detected with nested polymerase chain 
reaction (PCR) of the C. pneumoniae pst1 region,11 HSV-1 
gpD-1 region,12 VHH-6 U67 region,13 and T. gondii B1 
region.14 We reached sensitivities up to 9 copies/µL (for 
American Type Culture Collection [ATCC] VR-1356 
C. pneumoniae), 16 copies/µL (for ATCC VR-735 VHS-1), 
6 copies/µL (for ATCC VR-1480 VHH-6), and 10 copies/µL 
(for ATCC 50174 T. gondii). We standardized PCR con-
ditions to improve sensitivity (Table 1). We sequenced 
the amplified fragment in positive cases to demonstrate 
specificity. ACTB gene DNA was used as a control procedure 
(Gene-Link, Hawthorne, NY, USA).
statistical analyses
Pearson’s chi-squared test was used to compare qualitative 
variables (serum IgG and IgA and blood DNA). A P-value 
of 0.05 or less was considered statistically significant.
Results
Chlamydia pneumoniae
Finally, three studies were included in the meta-analysis15–17 
(see Table 2). All of these studies showed similar quality and 
Table 1 Nested-Pcr conditions for characterization of Chlamydia pneumoniae, hsV-1, hhV-6, and Toxoplasma gondii















initial denaturalization 94°c 4 min 94°c 4 min 94°c 1 min 94°c 1 min 94°c 2 min 94°c 1 min 94°c 1 min
Denaturalization 94°c 1 min 94°c 1 min 94°c 10 sec 94°c 10 sec 94°c 15 sec 94°c 10 sec 94°c 10 sec
hybridization 52°c 1 min 54°c 1 min 58°c 20 sec 67°c 20 sec 54°c 20 sec 57°c 10 sec 63°c 10 sec
extension 72°c 1 min 72°c 1 min 72°c 20 sec 72°c 20 sec 72°c 20 sec 72°c 30 sec 72°c 15 sec
Final extension 72°c 10 min 72°c 10 min 72°c 2 min 72°c 2 min 72°c 2 min 72°c 2 min 72°c 2 min
Number of cycles 40 40 35 30 40 40 40
Abbreviations: hhV, human herpes virus; hsV, herpes simplex virus; Pcr, polymerase chain reaction; min, minutes; sec, seconds.
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used blood and brain samples to detect bacterial DNA through 
PCR or nested-PCR. The meta-analysis revealed an associa-
tion between schizophrenia and C. pneumoniae (OR =5.96; 
95% CI =3.42–10.39; P0.001). However, our own results 
found no significant differences between cases and controls for 
IgG (P=0.521), IgA (P=0.885), and specific DNA measures 
because DNA was scarcely represented (see Table 3).
herpes simplex virus type 1 and human 
herpes virus 6
Fourteen studies were finally included in the meta-analysis 
for these two viruses (Table 2).18–31 The combined OR estima-
tion involving the 14 studies comparing detection of different 
markers for infection by HSV-1 in schizophrenic patients and 
healthy controls was 1.17 (95% CI =0.88–1.54; P=0.273). 
When heterogeneity tests were done, we obtained a value 
of χ2
exp
=15.4 (df=13; P=0.312), after which we could state 
that the differences found between the studies were due to 
randomness. This fact was corroborated by an I2 coefficient 
of 15.4%, indicating that only 15.4% of the variability of the 
ORs was due to the heterogeneity among studies.
As shown, in spite of the absence of important and, if any, 
nonsignificant heterogeneity (75%), a detailed study was 
carried out to consider the potential effect of some factors on 
the value of the overall OR through meta-regression, and it 
was concluded that the technique used to detect HSV-1 infec-
tion did not seem to affect OR value (P=0.274). Thus, we 
found no difference between risks arising from studies that 
detected DNA in brain tissue (OR =1.15; 95% CI =0.23–5.80) 
and that from studies in which serum antibodies were 
detected (OR =1.19; 95% CI =0.81–1.74).
Begg’s test was not significant (P=0.743), suggesting 
that there was a potential publishing bias. A similar result 
was obtained after Egger’s test (P=0.817). The quality of 
the studies examined was medium-high, and it was higher 
in the more-recent studies due to the introduction of quality 
validation scales, a fact that favored the control of the data 
included in the articles.
Finally, only three studies comparing infection by 
HHV-6 were included, all of them of acceptable quality 
(see Table 2).22,24,28 The statistical analysis could not confirm 
the existence of a significant association between infection by 
this virus and schizophrenia (OR =0.34; 95% CI =0.49–2.42; 
P=0.283). Our results about IgG, IgA, and specific DNA 
measures are detailed in Table 3. DNA was scarcely pres-
ent. No significant differences were found between cases 
and controls for these markers (P=1.000 for HSV-1 IgG; 
P=0.133 for HHV-6 IgG; P=1.000 for HHV-6 IgA), with the 
only exception being HSV-1 IgA, which was more frequently 
detected in controls than in cases (P=0.015).
Toxoplasma gondii
We included eight studies centered on the potential relation-
ship between T. gondii infection markers and schizophrenia 
as compared with healthy controls (Table 2).19,22,32–37 All these 
studies had similar weights, except for the one by Conejero-
Goldberg et al22 that used postmortem brain tissue samples, 
and thus included a smaller number of cases and controls; this 
study was also of lower quality according to the Newcastle-
Ottawa Scale. Due to their large sample size, the studies by 
Niebuhr et al35 and Mortensen et al34 stood out, the former 
being of the highest quality. The latter obtained the narrow-
est 95% CI range due to the large amount of participants 
included. After combining the different studies, we found a 
significant association between parasitation by T. gondii and 
schizophrenia (P=0.002); the combined OR was 2.50 (95% 
CI =1.40–4.47). We can therefore state that schizophrenia 
was 2.5 times more frequent in people in whom the marker 
for T. gondii was found when compared to people in whom it 
was not detected. The study by Conejero-Goldberg et al22 was 
the least-precise study and the one with the widest confidence 
interval. When heterogeneity tests were performed between 
the studies, a significant value was obtained: χ2
exp
=35.26 
with df=8, P0.0001. This result parallels an I2 coefficient 
equal to 77.3%, indicating that 77.3% of the variability of 
the ORs is due to the heterogeneity of the studies analyzed. 














Chlamydia pneumoniae samples (%) 41 (28.9) 47 (33.1) 0.521 29 (20.4) 31 (21.8) 0.885 2 (1.6) 0 (0)
hsV-1 samples (%) 125 (88.0) 124 (87.3) 1.000 12 (8.5) 27 (19.0) 0.015 1 (0.8) 2 (1.4)
hhV-6 samples (%) 112 (78.9) 100 (70.4) 0.133 3 (2.1) 4 (2.8) 1.000 1 (0.8) 2 (1.4)
Toxoplasma gondii samples (%) 56 (39.4) 29 (20.4) 0.001 1 (0.7) 2 (1.4) 0.624 1 (0.8) 0 (0)
Note: *DNa was scarcely present in samples, so the P-values were not calculated.
Abbreviations: iga, immunoglobulin a; igg, immunoglobulin g; hhV, human herpes virus; hsV, herpes simplex virus.





Such heterogeneity is explained by significant differences 
between reported risk at the only publication that detected T. 
gondii DNA in brain biopsies (OR =1.83; 95% CI =0.03–97.01; 
P=0.001) and risk reported by studies using detected serum 
antibodies (OR =2.74; 95% CI =1.33–5.62). Finally, even 
though Begg’s test was not significant (P=0.711), Egger’s test 
was (P=0.03), indicating a tendency to publish studies where 
results were significant, according to this last test.
Our own sample results on IgG, IgA, and specific DNA 
measures are detailed in Table 3. DNA was scarcely pres-
ent. No significant differences were found between cases 
and controls for IgA measures (P=0.624). However, IgG 




Previous studies describing a significant association 
between C. pneumoniae infection and the origin of schizo-
phrenia have been published15–17 (Table 2). Thus, Fellerhoff 
et al16,17 found DNA of C. pneumoniae in 15.3% of mono-
nuclear blood cells from patients with schizophrenia and 
11.8% in brain biopsies of these subjects. Finally, these 
authors described a significant improvement in psychotic 
symptoms in schizophrenic patients treated with azitromi-
cine. Moreover, a study showed an improvement in cogni-
tive functioning among schizophrenic patients treated with 
clozapine plus minocycline.38 The meta-analysis carried out 
in the present study reveals that C. pneumoniae is present in 
some patients and may be a potential etiological agent in 
schizophrenia.
This bacteria enters the organism via the respiratory 
system and it spreads using monocytes and lymphocytes 
reaching the central nervous system.39 Th1 lymphocytes are 
activated by exposure to bacterial antigens (in glial cells, for 
example), causing secretion of protoinflammatory cytokines 
(eg, interferon-γ), which, in turn, activate macrophages. 
Such macrophages increase indoleamine 2,3-dioxygenase 
(IDO) production, which converts tryptophan into kynurenic 
acid, hence diminishing tryptophan availability. In such a 
context, the pathogen cannot replicate itself. Intracellular 
kynurenic acid inhibits glutamine and nicotinic recep-
tors, which are responsible for cognitive impairment. An 
increased activity of IDO, which may be caused by the 
infection, has been described in genetically vulnerable 
patients with schizophrenia.40 The failure of this defensive 
mechanism produces persistent and chronic infections with 
intermittent replication,41 along with both maintained and 
insufficient levels of kynurenic acid. Prenatal administration 
of lipopolysaccharide seemed to decrease dopamine concen-
tration in rats’ frontal cortex whilst enhancing dopaminergic 
system activity in the striatum.42
Our own sample results do not show an association 
between C. pneumoniae infection and schizophrenia. The 
increased prevalence of C. pneumoniae infection in subjects 
without a respiratory illness may explain the lack of differ-
ences in antibody levels when comparing cases and controls.43 
Moreover, because the infection is focused on the central 
nervous system, it seems reasonable to detect microbial 
DNA in brain (that could be responsible for the illness) but 
not in peripheral blood.16 Nonetheless, limited sample power 
cannot be ruled out for this negative finding.
herpes simplex virus type 1 and human 
herpes virus 6
Different studies have explored the association between 
HSV-1/HHV-6 infections and schizophrenia, showing incon-
clusive results.6,18–29,34,35,44–52 Some of these studies have been 
included in our meta-analysis (Table 2). The lack of associa-
tion found in the meta-analysis may reflect a real absence of 
association or a type 2 error due to the use of indirect mea-
surements on brain samples. Only two previous studies have 
been able to find a significant association between HSV-1 
and schizophrenia.26,31 In such studies, authors postulate that 
maternal HSV-1 antibodies may cause fetal brain damage 
even in the absence of a fetal infection.
However, HSV-1 is neurotropic and mainly spreads in 
frontal and temporal brain regions in which certain impair-
ments could produce cognitive and memory alterations 
similar to those found in patients with schizophrenia.26,53 
Moreover, a controlled trial showed an improvement in cog-
nitive functioning among seropositive schizophrenic patients 
treated with one antipsychotic plus valacyclovir when com-
pared to those treated with the antipsychotic agent only.54 
Nevertheless, these results may be due to a simple clinical 
coincidence30 due to the high prevalence of this infection, as 
shown in other studies (Table 2). Also, regarding the possible 
role of the glutamate system, the association between muta-
tions in the specific GluN2B N-methyl-D-aspartate (NMDA) 
receptor subunit and maternal herpes simplex virus infection 
and schizophrenia,55 a disorder where brain activation and 
cortical neurotoxicity of NMDA receptor antagonists, has 
been extensively reported.56,57 In addition, schizophrenia has 
also been related to an interaction of prenatal immune acti-
vation and subsequent peripubertal stress.58,59 Furthermore, 
schizophrenia has also been linked with the effect of stress 
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on hippocampal neurogenesis,60 apoptosis, and parvalbumin 
expression.61,62
Our own sample results also failed to find any associa-
tion, and the clinical meaning of the increased frequency of 
IgA anti-HSV-1 among controls is not easily explainable. 
However, the cause of medical consultation may be asso-
ciated with a herpetic reactivation. This fact is difficult to 
demonstrate in a retrospective design and it is something 
that we did not take into account during our control recruit-
ment. Because such herpes virus associations do not have to 
involve a primary effect, and they cannot be detected from 
cross-sectional studies63 due to the high prevalence of the 
infection, future longitudinal studies are needed to conclude 
if there are causal associations between virus infections and 
psychiatric illness.
Toxoplasma gondii
In the last years, several kinds of studies (serological, phar-
macological, epidemiological, and behavioral studies) have 
been published on the association between T. gondii infec-
tion and changes in human behavior and neuropsychiatric 
disorders, including schizophrenia.19,22,32–35,37,44,46,51,64–74 There 
is clinical evidence supporting the interest of studying the role 
of T. gondii on such phenotypes: 1) higher titers of IgG anti-
toxoplasma have been found in the serum and cerebrospinal 
fluid of patients with early-onset and late-onset diagnostics; 
2) some antipsychotics (haloperidol, risperidone, fluphenazine) 
show anti-T. gondii activity; and 3) seropositive patients 
showed a predominance of positive symptoms.
Different meta-analyses on experimental studies focused 
on infection for T. gondii have been published. Results 
are congruent enough with the existence of an association 
between infection for T. gondii and schizophrenia. Our 
current meta-analysis OR values are very similar to those 
reported earlier, namely: OR =2.73 (95% CI =2.10–3.60; 
P0.001) in the study by Torrey et al75 and OR =2.70 
(95% CI =1.34–4.42; P=0.005) in our group’s previous 
meta-analysis.6 According to these results, we could say 
that schizophrenia was 2.7 times more frequent in people 
infected by T. gondii than in people with no signals of this 
infection. Thus, T. gondii may indeed play a key role in the 
etiology of schizophrenia.
In our present meta-analysis, which includes the most-
recent publications on the field, schizophrenia was found 
to be 2.5 times more frequent in people with a previous 
T. gondii infection than in subjects with no signals of having 
been under the effects of a T. gondii infection. However, we 
have to point out that heterogeneity tests and publication bias 
were also significant. Studies supporting this positive finding 
were: 1) larger studies, where it is more difficult to detect 
differences, and 2) studies involving soldiers who showed 
an increased seroprevalence, probably due to their lifestyles. 
But the significant OR may also be due to a higher prevalence 
of antibodies acquired after the onset of the disease, due to, 
for instance, bad hygienic habits.69
In hypothesis, a previous neurological injury caused by 
the parasite, and the consequent inflammatory response,76 
may activate astrocyte function, increasing levels of intrac-
erebral kynurenic acid the toxicity of which acts to inhibit 
glutamine and nicotinic receptors. These changes are believed 
to be related to serotonin and melatonin deficits, which would 
contribute to increased cognitive impairment.67,77 Such mech-
anism has also been suggested for C. pneumoniae. Increased 
levels of dopamine in the central nervous system is another 
consequence of T. gondii infection.78 This effect would be 
modulated through genes involved in tyrosin–hydroxilase 
synthesis, which metabolizes L-tyrosine into dihydroxyphe-
nylalanine (a dopamine precursor) and could explain some 
behavioral and motor symptoms.79 Also, T. gondii has been 
shown to induce elevated levels of central nervous system 
dopamine in experimentally infected animals.80
Since most of the previous studies have not detected 
an increase of anti-toxoplasma immunoglobulin M, it is 
thought that manifestations are a consequence of a parasite 
reactivation. However, the study of parasitism is especially 
important because the first infection occurs in the fetus and 
produces a congenital toxoplasmosis with neurodevelop-
mental consequences.81 These alterations might be evident 
only later in life, maybe coinciding with the start of gray 
matter degeneration after puberty.82 Some disorders, such as 
chorioretinitis, also appear in subjects around 20–30 years 
old and could have a similar pathogenesis.77 This fact is sup-
ported by serological studies34,65 showing increased levels 
of IgG in mothers and newborns who are at higher risk for 
schizophrenia in adult life. Finally, Xiao et al74 described an 
association between T. gondii genotype I fetal infection and 
schizophrenia. This genotype is responsible for up to 75% of 
congenital toxoplasmosis in Spain.83 Thus, there seems to be 
a plausible connection between primary maternal parasitism 
and increased risk for schizophrenia in the offspring.69
We also found that anti-T. gondii IgG was more frequent 
in patients with schizophrenia than in controls, supporting 
the possibility of a previous infection with a possible intra-
cerebral inflammatory response. DNA studies using blood 
samples were not significant. This would be in agreement 
with poor systemic consequences in the process.






The present meta-analysis shows that C. pneumoniae DNA 
(measured both in blood and brain) is significantly more 
frequent in patients with schizophrenia than in controls. 
A significant association was also detected between T. gondii 
parasitism and schizophrenia, even after controlling for pub-
lication bias. In addition, in the analysis performed in our 
own sample, we found an important relationship between the 
illness and the presence of IgG anti-T. gondii, which may 
suggest the potential interest of detecting such parasitism to 
develop potential prevention strategies. Finally, we think that 
new studies are needed to have robust, and more conclusive 
results. We need prospective and comparative studies, with 
larger patient and control samples and using combined micro-
biological techniques for the analysis of the same subject 
and sample. Future studies should also take into account 
the illness phase and analyze blood, cerebrospinal fluid, and 
brain tissues simultaneously using standardized, sensitive, 
and appropriate techniques, including, if possible, pregnant 
women and their offspring as subjects under analysis.
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